Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Tofacitinib (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A18-28. July 27, 2018. (IQWiG reports; Volume 652).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Tofacitinib (rheumatoid arthritis) – Addendum to commission A18-28. Commission A18-56. October 04, 2018. (IQWiG reports; Volume 673).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Tofacitinib (rheumatoid arthritis) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A17-18. July 28, 2017. (IQWiG reports; Volume 525 ).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Tofacitinib (rheumatoid arthritis) – Addendum to commission A17-18. Commission A17-43. September 28, 2017. (IQWiG reports; Volume 545).
IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.